LICENSE AGREEMENTS (Details)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2012 USD ($)	Sep. 30, 2022 USD ($) item	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) item	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Revenue		$ 94,000	$ 2,030,000	$ 2,705,000	$ 4,368,000
TG-1101 [Member]
Upfront fee	$ 2,000,000.0			2,000,000		$ 2,000,000
Income taxes	$ 300,000
Revenue		38,000	$ 38,000	114,000	$ 114,000
Term after first commercial sale	15 years
Deferred Revenue		500,000		500,000		600,000
Deferred Revenue, Current		200,000		200,000		200,000
TG-1101 [Member] | Maximum [Member]
Potential milestones payable		5,000,000.0		5,000,000.0
Tgr 1202 Umbralisib [Member]
Additional payments on achievement of certain milestones		$ 150,000,000.0		$ 150,000,000.0
Number of oncology indications | item		2		2
Number of non oncology indications | item		1		1
TGR-1202 [Member]
Expenses incurred				$ 24,000,000.0
Royalty Expense				200,000		$ 200,000
Royalty payable		$ 4,700,000		4,700,000
LFB License Agreement
Additional payments on achievement of certain milestones		13,000,000.0		$ 13,000,000.0
LFB Group [Member]
Term after first commercial sale				15 years
Additional payments on achievement of certain milestones		$ 18,000,000.0		$ 18,000,000.0